The "Academician Think Tank" enters enterprises to diagnose and assist development

On May 9th, under the arrangement of the "2024 Issue 1 Lushan Dialogue - Academician Visit to Ji'an in the Biopharmaceutical Industry" event, experts including Li Song, Academician of the Chinese Academy of Engineering and Deputy Director of the Medical and Health Division, and Chen Shilin, Academician of the Chinese Academy of Engineering and Chief Professor of Chengdu University of Traditional Chinese Medicine, visited Jiangsheng to investigate our company's biopharmaceutical technology innovation. Zhong Wu, Director and Researcher of the National Emergency Prevention and Control Drug Engineering Technology Research Center of the Military Medical Research Institute, accompanied them, along with city leaders Liu Zhibin and Zhou Mi, and district management committee leader Huang Mingchun. The company's general manager warmly received and participated in the district symposium.
This event aims to fully leverage the intellectual and technological resource advantages of academicians, experts, and their teams to promote high-quality development of enterprises. In the corporate culture exhibition hall, the general manager gave the academicians and experts a detailed introduction to Jiangsheng's development history, product features, and technological innovations.

During the investigation, the academicians and experts frequently asked questions and offered many valuable guiding suggestions. Academician Li Song pointed out that biopharmaceutical companies must dare to face the forefront of global medical science and technology, be pioneers, and overcome difficulties. Based on the characteristics of the company's biopharmaceutical products, Academician Li Song proposed jointly developing research on the application of humanized bovine polyclonal antibodies with the company. This visit by the academicians and experts provided many high-level guiding suggestions for the company's development. The company looks forward to strengthening cooperation with the academician team in the development and application of humanized bovine polyclonal antibodies.

This visit by the academicians and experts diagnosed and assessed the company, providing new ideas for the company's technological innovation, finding new directions for multiple scientific and technological bottlenecks, and laying confidence for the company's high-quality development in the biopharmaceutical field.